secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mirati Therapeutics, Inc. (—)
CIK:        0001576263
Form:       8-K
Filed at:   2024-01-23T23:59:59+00:00
Accession:  0001140361-24-003287
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.02, 2.01, 3.01, 5.01, 8.01, 3.03, 5.03, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mirati acquired by Bristol-Myers Squibb for $58/share plus contingent $12 CVR; merger closes
--------------------------------------------------------------------------------

- Merger closed Jan 23, 2024; each Mirati share converted into $58 cash plus one CVR with potential $12 milestone payment.
- Aggregate purchase price approx. $4.8B in equity value, funded by BMS cash and debt.
- CVR milestone: submission and FDA acceptance of NDA for MRTX1719 in non-small cell lung cancer (1st-3rd line) by Jan 23, 2031.
- Mirati's board resigned; new board from Bristol-Myers appointed; equity and 401(k) plans terminated.
- Mirati common stock delisted from Nasdaq as of Jan 23, 2024; company will file Form 15 to suspend reporting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576263/000114036124003287/0001140361-24-003287-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576263/000114036124003287/n70019397x1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-003287

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer